RICHMOND, Va., Oct. 15, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) this week published compelling results from a multicenter, open-label clinical trial published in JAMA Network Open. Two ...

Patients not already receiving buprenorphine can receive the first injection of Sublocade following a single dose of transmucosal buprenorphine and a 1 hour observation period to confirm tolerability.

RICHMOND - Indivior PLC (NASDAQ:INDV), a pharmaceutical company with a market capitalization of $3.1 billion and an impressive 207% return over the past year, announced Wednesday that a new clinical ...

Indivior recently released results from a multicenter, open-label clinical trial showing that rapid induction with SUBLOCADE, using a single 4 mg oral buprenorphine dose followed by a same-day ...

Indivior PLC, a global leader in addiction treatment, announced that the US Food and Drug Administration (FDA) has approved label changes for Sublocade including a rapid initiation protocol and ...

PDUFA date set for February 7, 2025 If approved by the FDA, label would expand to include alternative injection sites in the thigh, buttock and back of the arm for induction and maintenance as well as ...

About The Study: In this multicenter randomized clinical trial, rapid induction had higher retention than standard induction overall and in patients who tested positive for fentanyl through ...